PA
JUNO

Pinnacle Associates’s Juno Therapeutics, Inc. JUNO Stock Holding History

Pinnacle Associates’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,020
Closed -$275K – 722
2017
Q4 		$275K Sell
6,020
-110
-2% -$5.49K 0.01% 581
2017
Q3 		$275K Buy
+6,130
New +$209K 0.01% 583

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Pinnacle Associates's JUNO Position: Q1 2018 in Review

Pinnacle Associates sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 6,020 shares — an estimated $275K sold.

Pinnacle Associates first reported a position in JUNO in Q3 2017 and held it in 2 quarters. The position peaked at $275K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Pinnacle Associates reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Pinnacle Associates sold 6,020 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $275K.
  • Pinnacle Associates first reported a position in Juno Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
  • Pinnacle Associates's Juno Therapeutics, Inc. position peaked at $275K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Pinnacle Associates's 13F filing for Q1 2018, filed 11 May 2018.